Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Tumors (NETs)

Next Previous
Trial Profile

A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Tumors (NETs)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SVN53-67-M57-KLH peptide vaccine (Primary) ; Temozolomide (Primary)
  • Indications Gastrointestinal cancer; Lung cancer; Neuroendocrine carcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 22 Jan 2025 Planned initiation date changed from 15 Dec 2024 to 15 Jun 2025.
  • 01 Nov 2024 Planned initiation date changed from 15 Oct 2024 to 15 Dec 2024.
  • 02 Aug 2024 Planned End Date changed from 15 Jan 2028 to 15 Oct 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top